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Abstract
Background: Mutation of the IL2RG gene results in a form of severe combined immune deficiency (SCID-X1),
which has been treated successfully with hematopoietic stem cell gene therapy. SCID-X1 gene therapy results in
reconstitution of the previously lacking T cell compartment, allowing analysis of the roles of T cell immunity in
humans by comparing before and after gene correction.
Methods: Here we interrogate T cell reconstitution using four forms of high throughput analysis. (1) Estimation of
the numbers of transduced progenitor cells by monitoring unique positions of integration of the therapeutic gene
transfer vector. (2) Estimation of T cell population structure by sequencing of the recombined T cell receptor (TCR)
beta locus. (3) Metagenomic analysis of microbial populations in oropharyngeal, nasopharyngeal, and gut samples.
(4) Metagenomic analysis of viral populations in gut samples.
Results: Comparison of progenitor and mature T cell populations allowed estimation of a minimum number of cell
divisions needed to generate the observed populations. Analysis of microbial populations showed the effects of
immune reconstitution, including normalization of gut microbiota and clearance of viral infections. Metagenomic
analysis revealed enrichment of genes for antibiotic resistance in gene-corrected subjects relative to healthy
controls, likely a result of higher healthcare exposure.
Conclusions: This multi-omic approach enables the characterization of multiple effects of SCID-X1 gene therapy,
including T cell repertoire reconstitution, estimation of numbers of cell divisions between progenitors and daughter
T cells, normalization of the microbiome, clearance of microbial pathogens, and modulations in antibiotic resistance
gene levels. Together, these results quantify several aspects of the long-term efficacy of gene therapy for SCID-X1.
This study includes data from ClinicalTrials.gov numbers NCT01410019, NCT01175239, and NCT01129544.
Background
Several primary immunodeficiencies have been treated
successfully by gene correction of hematopoietic stem
cells (HSC) with integrating vectors [1–9]. This therapeutic
strategy has benefited many patients and in addition pro-
vides a unique window to study mechanisms associated
with immune reconstitution. In X-linked severe combined
immunodeficiency (SCID-X1), the first primary immuno-
deficiency treated successfully by gene transfer, patients
harbor mutations in the IL2RG gene, which encodes the
common gamma chain, a component of several cytokine
receptors important in T and NK cell growth and develop-
ment [10–12]. Patients typically lack these cells before cor-
rection [13–15], but afterwards show robust T cell and
transient NK cell reconstitution accompanied by consider-
able restoration of immune function [6–9]. SCID-X1 gene
therapy thus provides a unique opportunity to study the
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consequences of T cell function in previously deficient hu-
man subjects.
In the first gene therapy trial to treat SCID-X1 (de-
noted here “SCIDn1”), early designs of gammaretroviral
vectors were used [6–9], which were the only vector type
available at the time. These vectors contained strong en-
hancers as part of the long terminal repeat (LTR) of the
Moloney murine leukemia virus (MLV) retroviral back-
bone. The enhancers, along with the LTR promoter se-
quence, supported efficient expression of the corrective
IL2RG gene and allowed successful gene correction.
However, subsequent experience implicated these vec-
tors in insertional mutagenesis, in which vector signals
activated transcription of host proto-oncogenes, in some
cases associated with severe adverse events [16–18].
A second trial (SCIDn2) was carried out to treat
SCID-X1 using an improved self-inactivated vector in
which the LTR strong enhancer sequences were deleted
[19], and a promoter comprised of the short elongation
factor 1 alpha (EF1a) promoter, devoid of enhancer re-
gions, was used to express the therapeutic IL2RG gene.
T cell numbers after correction were indistinguishable
in the first and second trials. So far, no severe adverse
events have been linked to insertional activation in the
SCIDn2 trial after a median follow-up of 6 years for
seven patients.
In this study, we used several high throughput sequence-
based methods to analyze samples from the SCID-X1 trials,
with the goal of probing immune mechanisms and the
resulting effects on microbial communities. To assess the
number and distributions of gene-corrected precursor cells
producing T cells, deep sequencing of sites of vector inte-
gration was used [16–27], where each unique integration
site putatively marked a distinct T cell progenitor. T cell de-
velopment could be followed at a later step by using DNA
sequencing to track rearrangements of gene segments en-
coding the T cell receptor-beta CDR3 region [28–32]. Im-
mune cells contribute to control of the resident microbiota,
so the consequences of T cell reconstitution were assessed
by deep sequencing of oral, fecal, and nare samples to
characterize the full microbiota using shotgun metage-
nomics. In a separate analysis, the viral content in fecal
samples was monitored through the enrichment, purifica-
tion, and sequencing of RNA- and DNA-containing viral
particles.
The data support a wealth of new inferences on T cell
growth and immune activity after reconstitution. For
example, a minimum estimate for the numbers of cell
divisions between progenitor cells and mature T cells
was developed by comparing population sizes from in-
tegration site and T cell receptor (TCR) sequence data.
TCR diversity could be compared for selected samples
from the SCIDn1 and SCIDn2 trials, providing infor-
mation on the durability of reconstitution and effects of
adverse events on TCR diversity. In the microbiome
data, normalization of microbial communities was doc-
umented following successful treatment in several sub-
jects. Viral infections, several not detected clinically,
could be shown to be widespread but often cleared with
immune reconstitution. Thus, these data begin to out-
line the utility of “multi-omics” analysis of gene correc-
tion in primary immunodeficiency.
Methods
Human subjects
Patients were recruited as described [19, 33]. We collected
the same sample types from six healthy children between
the ages of 21–43 months under IRB 13-010072. We ob-
tained sorted CD3+ T cells from three anonymous healthy
adult donors above the age of 18 from the Human Im-
munology Core at the University of Pennsylvania. All sam-
ples were stored at − 80 °C.
Integration site analytical methods
Integration site sequences were determined using two
different methods due to changes in technology over the
period of patient monitoring (details in Additional file 1:
Table S2). In the first, 454/Roche pyrosequencing was
used to determine integration site placement [24]. In
the second, Illumina paired end sequencing was used
[21, 26, 27, 34]. In both, DNA was broken using shear-
ing or restriction enzyme cleavage, then DNA adaptors
ligated on to the broken DNA ends. Nested PCR was
then used to amplify from the linker to the integrated
vector, and the intervening segment of human DNA se-
quenced. All integration site sequence analysis was be
carried out in quadruplicate to minimize PCR jackpot-
ting. All sample sets were worked up together with human
DNA lacking integrated lentiviral sequences to monitor for
PCR contamination, which was typically undetectable. Dif-
ferent linkers were used for ligation-mediated PCR for each
sample in a set to block PCR cross over. All samples were
bar coded on both ends of the molecule, and only those
with correct bar code pairs analyzed, thereby suppressing
artefactual molecules resulting from PCR recombination.
A total of 31 samples were analyzed, yielding a total of
24,170 integration sites.
TCR sequence analysis
TCR sequencing was performed on whole blood samples
that had been fractionated to yield T cell (CD3+) or
PBMC fractions. Genomic DNA was isolated and se-
quenced at Adaptive Biotechnologies using their immu-
noSeq protocol to determine CDR3 region sequences of
the TCR-beta locus [35]. The protocol uses proprietary
primer design and post-processing steps to implement
controls, adjust for bias, and detect gene segments and
sequence productivity. Data were analyzed using the
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immunoSeq Analyzer version 3.0. A total of 40 samples
were analyzed, yielding a total of 32 million TCRB se-
quences. All statistics were performed only on the part of
the clonal population for which a productive rearrange-
ment was detected.
Microbiome sequencing
DNA was isolated from fecal, oral, and nare samples
using the following procedures: Small aliquots of fecal
material (< = 1 ml) and the tips of each swab (for oral
and nares swabs) were deposited into a PowerSoil bead
tube. DNA was extracted using the standard MoBio
PowerSoil DNA extraction protocol, with one or more
blank extraction controls worked up simultaneously with
each set of samples. Work spaces were decontaminated
using bleach and UV irradiation. The resulting DNA
from all samples and blank controls was sequenced on
an Illumina HiSeq 2500 using NextSeq chemistry and
standard Illumina dual barcoding for each sample.
Due to artifacts in genomic sequences for members of
the Apicomplexa family, many reads from a common water
contaminant (Bradyrhizobium) were cross-annotated as be-
longing to Apicomplexa. Consequently, we removed all
Apicomplexa reads before further analysis due to their un-
certain provenance.
Virome analytical methods
Viral particles were isolated from a subset of the fecal
samples using a protocol adapted from [36]. Fecal sam-
ples were homogenized and filtered through a 0.4-μm
filter. The filtered samples were then treated with DNase
and RNAseq to remove exogenous nucleic acids. Com-
bined nucleic acids were then purified from the sample
using the Qiagen UltraSens Virus Kit.
To obtain DNA viruses, we amplified viral genomes in
an aliquot of the combined nucleic acids using the Illus-
tra Genomiphi V2 DNA amplification kit. Resulting
amplified DNA was quantified using PicoGreen and
stored at − 20 °C. To obtain RNA viruses, we treated a
separate aliquot of the combined nucleic acids with
DNAse+ and then performed reverse transcription of
the RNA to cDNA using the SuperScriptIII First-Strand
Synthesis System from Life Technologies and second
strand synthesis using Sequenase. The resulting cDNA
was quantified with PicoGreen and stored at − 20 °C.
Resulting DNA was prepared and sequenced using
NextSeq for library preparation and an Illumina HiSeq
2500 for sequence acquisition. The same post-processing
pipeline was used, including all quality-control, host re-
moval, and read annotation steps. For analysis, we con-
sidered only reads that fell under the virus classification
and removed the following viral annotations as being re-
agent contamination [37, 38]: Enterobacteria phage M13,
Enterobacteria phage T7, Enterobacteria phage phiX-174
sensu lato, Bacillus phage phi29, and Pseudomonas phage
phi6, human herpesvirus 6 and 7, and Shamonda virus. In-
fluenza sequences were detected, but only the HA seg-
ment was found. The HA sequence matched sequences
from a previous run of the sequencing instrument, and so
were excluded as carry over.
Bioinformatic methods
To estimate population sizes of T cell progenitors from
integration sites, we used Chao1, and of TCR sequence
data, we used Chao2.
Sequence reads for all metagenomic samples were
processed using the Sunbeam pipeline (https://github.
com/sunbeam-labs/sunbeam). Reads were quality-
controlled by trimming low-quality bases and adapter
sequences using Trimmomatic [39], and host reads
were removed using BWA [40]. The remaining reads
were filtered for low-complexity sequences using dust-
masker [41] and Komplexity (https://github.com/eclarke/
komplexity). The reads that remained were assigned tax-
onomy via Kraken [42] and a custom database built on all
microbial genomic sequences in RefSeq release 79 [43].
Antibiotic resistance gene levels were assessed using
ShortBRED [44] and a marker gene database built from
CARD [45] available on the ShortBRED website (https://
bitbucket.org/biobakery/shortbred/downloads/ShortBRED_
CARD_2017_markers.faa.gz). The same reads used as input
to the Kraken taxonomic classifier were used as input to
ShortBRED.
T cell receptor antigen recognition was queried using
VDJdb [46], a database and software package that com-
pares CDR3 regions from TCR sequencing experiments
to public epitope databases. The software compared our
TCRB sequences to human TCRB sequences in the data-
base with allowances for low numbers of indels and sub-
stitutions (default parameters), and only matches with
high confidence (VDJdb score > 2) were kept.
Final analysis and figure generation were performed using
the R statistical software [47]. Bray-Curtis dissimilarity and
other ecological metrics were calculated using the R pack-
age vegan [48]. The full code listing and post-processed
data used for analysis and figures are available online at
https://github.com/eclarke/scid-multiomics-paper.
Results
Experimental strategy
Our comparative analysis of gene-corrected progenitors
and daughter T cells focused on nine patients from the
SCIDn2 trial [19] and five patients from the SCIDn1 trial
[8] for whom samples were available (Fig. 1a). Patient
characteristics are summarized in Additional file 1:
Table S1. Two of the subjects from the SCIDn1 trial de-
veloped leukemia requiring chemotherapy: F107 and
F110 at 68 months and 33 months, respectively, after
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infusion of gene-modified progenitor cells [8, 19, 25].
The samples for these patients analyzed here are well
after these adverse events, allowing assessment of the
effects of leukemia and chemotherapy on progenitor
cell and T cell populations. One subject in the SCIDn2
trial, U205, was transplanted twice—T cell numbers
failed to reach a clinical protocol end point after the
first infusion with modified cells, but succeeded the
second time. Samples from the two treatment periods
are designated U205 and U205b. Patient U204 was not
successfully reconstituted but was rescued after allo-
geneic stem cell transplantation.
A
B
Fig. 1 Sampling schedule for 14 SCID-X1 gene-corrected subjects studied for integration site distributions and TCRB CDR3 sequence composition.
a Times of sample acquisition after cell infusion. b Population sizes of inferred progenitor cells deduced from marking with unique sites of vector
integration. Integration site data is in Additional file 1: Table S2, and summaries of genes near sites of vector integration are in Additional file 2:
Figure S1. The x-axis shows the time since cell infusion. The y-axis shows the population size reconstructed using Chao1 from the numbers of
unique integration sites and replicate sampling. Samples are named for the site of gene correction (U indicates USA, F indicates France; the next
digit indicates the trial 1 = SCIDn1, 2 = SCIDn2, and the next two digits indicate the patient number within that trial). Patients F107 and F110
suffered severe adverse events at months 68 and 33, respectively. Both recovered by the final timepoints listed
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Vector integration sites and the T cell repertoire were
monitored through regular per-protocol blood draws,
followed by isolation of CD3+ populations. Sorted cells
were subject to DNA extraction and then amplification
of either integration sites (mostly previously reported in
[8, 19, 25]; Additional file 1: Table S2) or mature TCR-
beta loci (Additional file 1: Table S3; new data here),
followed by sequencing. Vector integration sites mark pro-
genitor cells capable of differentiating into mature periph-
eral T cells. Rearranged TCR-beta loci identify mature T
cells present in the blood. Time points from the integra-
tion site analysis were chosen to match those used in the
TCR analysis—characterization of additional time points
for integration site distributions in SCID-X1 gene therapy
was published previously [8, 18, 19, 33, 49–51].
Microbiome samples were available for six SCIDn2 pa-
tients (U201, U203, U204, U205, U207, and F201). Oral,
nasal, and gut microbiota were sampled via collection of
oropharyngeal swabs, nasopharyngeal swabs, and stool
samples. Sampling times ranged from 4 to 181 months
post infusion of corrected cells. Sample acquisition was
at times limited by clinical and practical considerations.
As controls, we analyzed TCR-beta sequences from
CD3+ cells from five healthy children and three healthy
adults after informed consent. Healthy subject demo-
graphics are in Additional file 1: Table S1. Cross-sectional
microbiome samples were collected from the same sub-
jects and analyzed along with the SCID gene-corrected
samples.
Integration site analysis
To characterize the hematopoietic progenitor cells
capable of differentiating into peripheral blood T cells,
we determined the sites of vector integration in patient
chromosomes. Because of the large size of the human
genome, each integration site uniquely marks a precur-
sor cell capable of additional division after integration
of the vector. Summaries of genes near integration
sites in the most expanded clones at each time point
are in Additional file 2, Figure S1. The numbers of in-
tegration sites detected in purified T cell samples
ranged widely, from as few as 62 to as many as 2009.
Reconstruction of population sizes using the Chao1 es-
timator suggested minimal sizes of 144 to 6018 active
progenitors.
For the SCIDn2 subjects, we found that the estimated
total number of vector integration sites was relatively
constant over the time intervals analyzed (Fig. 1b), in
the range of ~ 1000 predominant clones yielding circu-
lating cells (Additional file 1: Table S2). Numbers varied
by subject, with subject U203 showing consistently higher
levels, while U205, a subject in which a suboptimal num-
ber of gene-modified cells were delivered, showing con-
sistently lower levels.
For the SCIDn1 subjects, numbers of unique sites
identified varied from 263 to 682; reconstructed minimal
population sizes ranged from 628 to 1287. Comparison
of mean values shows no difference in the numbers of
unique integration sites in SCIDn2 subjects compared to
SCIDn1 subjects (p = 0.17, Wilcoxon rank-sum test).
Population sizes of progenitors were compared be-
tween SCIDn1 subjects who suffered adverse events and
were treated with chemotherapy (F107, F110) versus
those who did not (F102, F106), or versus SCIDn2 sub-
jects. Treating time points as independent tests, no system-
atic differences were detected comparing within SCIDn1
subjects; a modest difference in median values was detected
with a comparison of adverse events versus no adverse
events (adverse event samples compared to pooled SCIDn1
and 2; p = 0.041, Wilcoxon rank-sum test). Thus, the data
suggest that adverse events and chemotherapy may have di-
minished the pool size, though we note that these subjects
were also at relatively long times after gene therapy, so
slow loss of diversity over time is a potential alternative
explanation.
TCR-beta CDR3 analysis
Clonal structure of T cell populations was investigated
by analyzing TCR-beta rearrangements in genomic DNA
from peripheral blood CD3+ cells (Fig. 2). CDR3 region
nucleotide sequences were conceptually translated into
amino acid sequences, and numbers of productive rear-
rangements quantified (Fig. 2a). All the following analysis
focused on T cell clones with productive rearrangements.
For healthy adults, productive rearrangements ranged
from 18,000 to 27,000 per sample. For healthy children,
numbers ranged from 18,000 to 22,000 per sample. For
SCIDn2, most samples were close to this range (12,000 to
33,000 per sample; no significant difference in medians).
For SCIDn1, results were slightly lower, with four out of
five samples between 15,000 and 23,000. The exceptional
sample was from subject F107 who only showed 5,000
unique CDR3 sequences. F107 both suffered an adverse
event at month 68 and was treated by chemotherapy, and
demonstrated a low number of engrafted gene-modified
cells at baseline. Patient F110 was also treated by chemo-
therapy following a serious adverse event at month 33, but
was initially treated with a higher dose of gene-modified
cells, potentially explaining the higher diversity in this
patient.
For all the CDR3 samples studied, we could only sam-
ple a small fraction of the total CDR3 clonotypes in the
subjects. To account for this, we used replicate sampling
and the Chao2 population estimator to estimate a mini-
mum bound for the true number of CDR3 clonotypes
(Additional file 1: Table S3). Estimators can be sensitive
to sampling effort, so our estimates represent minimum
values. Focusing on samples analyzed with multiple
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AB
C
D
E
F
Fig. 2 Analysis of TCRB CDR3 sequences. a The unique numbers of rearranged genes detected are shown. The colors indicate in frame rearrangements
(blue), frameshifts (tan), and stop codons (red). b Richness and evenness of the inferred TCRB CDR3 populations. Patients are color coded as indicated
on the right, and all replicates for each patient timepoint displayed. The ranges of healthy adults and children are shown by the light and dark gray
diamonds, respectively. c Clustering of the samples sequenced using Bray-Curtis similarity and t-SNE. The association of patients with samples is shown
by the key at the right. d V gene usage. The patient of origin is marked at the top of each panel. The V genes shown were the top most commonly
found V genes in healthy children, ordered by prevalence; not all V genes used by each patient are shown. All panels show the same x-axis of V genes.
Chi-squared test used to assess differences between gene distribution in patients compared to healthy children; red label indicates significant difference
from healthy (p< 0.05). e J gene usage, with J genes determined by the same manner as in D. f Heat map summarizing the frequencies of utilization of
the most common V and J pairs. Subjects studied are marked at the top. Time of sampling is shown on the right
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replicates, we estimate population sizes of 26,000 to
2,600,000 CDR3 variants. The median for SCIDn2 sam-
ples was not different from that of healthy children, but
the median for SCIDn1 was significantly lower than for
the healthy children (p = 0.026; Wilcoxon rank-sum test),
possibly due to the much longer follow-up time available
for the SCIDn1 patients. Analysis of trends over time
suggested that subjects U201, U203, and U207 reper-
toires became more rich over time (Fig. 2b). The one ex-
ception was the case of suboptimal reconstitution (U205),
which did not show longitudinal increase.
To begin to characterize repertoire composition, we
used Bray-Curtis dissimilarity and t-SNE to cluster sam-
ples (Fig. 2c). Replicates from each subject closely resem-
bled those from the same subject at different time points,
but differed from other subjects. No systematic differences
were observed comparing SCIDn1 and SCIDn2, or com-
paring either data set to healthy controls (PERMANOVA
test on Bray-Curtis dissimilarity, n.s.).
Recombination involving the most frequently used V
(Fig. 2d) and J (Fig. 2e) gene segments was next quanti-
fied and compared. Usage of gene segments was quanti-
fied for healthy children and averaged, then the profile
was compared to gene-corrected SCID subjects. The
great majority of gene-corrected samples did not show
significant differences from the distribution in healthy
children, in the analysis of either V or J gene segment
usage (chi-squared test). The only exception was V gene
usage in early time points for SCIDn2 subject U201
(chi-squared test, p < 0.05). This subject was successfully
corrected, so the unusual heavy use of specific V gene
segments is not indicative of clinical failure. Of possible
significance, U201 had an ulcer on his palate of un-
known origin that became inflamed as T cells were pro-
duced, possibly skewing the repertoire. Fig. 2f shows the
usage of V-J pairs within subjects, emphasizing the occa-
sional outgrowth of expanded clones, potentially in re-
sponse to antigen, followed by decrease of abundance.
TCR sequences were scanned for evidence of public
epitopes in order to assess whether the subjects had
formed typical responses to common antigens. However,
no clear-cut link was found between putative epitopes
and the microbial and viral taxa described below.
Tracking T cell ontogeny
Comparison of the estimated lower bounds for the num-
ber of unique integration sites per sample with the num-
ber of unique TCR sequences allows estimation of the
minimum number of cell divisions required to generate
the TCR-beta cell population from gene-corrected pre-
cursors (Fig. 3). We calculated the minimum number of
cell divisions as the base-2 logarithm of the difference
between the estimated population size of unique T cells
and the estimated population size of integration sites:
CellDivisions ¼ log2 TCRs−IntSitesð Þ
We found a relatively consistent range of minimum
cell division values across patients and timepoints, with
a median of 9.1 and a minimum and maximum of 5.6
and 15.4. The fraction of progenitor cells that die in the
thymus is unknown, so our estimates are lower bounds
for the required number of cell divisions.
Fig. 3 Minimum numbers of cell divisions between progenitors and daughter T cells. The x-axis shows time after corrected cell infusion. The
y-axis shows the estimated number of cell divisions calculated as described in the text. The subjects studied are indicated beneath the figure as
indicated by the color code. Circles indicate subjects from the second trial, and squares indicate subjects from the first. Stars next to the points
indicate PBMCs were sequenced rather than sorted CDR3+ cells. Replicates were not available for U205b and so this subject was not analyzed
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Response of the microbiome to T cell reconstitution
Microbiota community structure was analyzed for six
gene-corrected subjects (Fig. 4a) by extraction of DNA
from swabs (oral and nares samples) or stool, followed
by shotgun metagenomic sequencing (samples analyzed
are in Table S4; summaries of clinical infections are in
Table S5). Numbers of samples available per subject
ranged from one to seven. The numbers of sequences
acquired per sample averaged 72,000 (nasal; Fig. 4b),
8,746,000 (fecal; Fig. 4c), and 3,625,000 (oral; Fig. 4d).
Sequencing reads were quality filtered as described in
the “Methods” section and then assigned to microbial
taxa using Kraken [42] .
The analysis of gut microbiota (Fig. 4c) emphasized
the differences between gut microbiota of healthy chil-
dren (right columns) versus SCID gene-corrected sub-
jects (left columns). The healthy subjects were colonized
predominantly with Bacteroides, which is typical of healthy
gut, whereas the SCID subjects showed a range of major
colonists. U201 was colonized mainly with Bifidobacteria,
which is characteristic of healthy breast-fed babies [52].
However, the guts of subjects U203 and U205 were
A B
C D
Fig. 4 Longitudinal analysis of the microbiome during SCID-X1 gene correction. a Timing of sample acquisition. b Longitudinal analysis of the
nasopharyngeal microbiome. Each column indicates a sample. Samples are grouped by subject as indicated at the top. Each row summarizes the
proportions of a specific microbial taxa inferred using Kraken. Abundance is color coded as indicated to the right and reflects the number of
reads assigned to that taxa as a proportion of all non-human reads. c As in B, but oropharyngeal samples. d As in B, but stool samples
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colonized with Veillonella at early timepoints. As Veillo-
nella is commonly an oral bacteria, this is suggestive of ab-
normal colonization. Subject U204 showed high-level
colonization with Enterobacteriaceae, typical of dysbiotic
states. Early samples from subjects U207 and F201 showed
abundant representation of Adenovirus and Bocavirus in
the gut (Fig. 4c, bottom rows), comprising a significant
portion of the classified taxa even though whole stool (and
not virus-enriched material) was sequenced.
Oral samples (Fig. 4d) from the healthy controls were
dominated by typical oral bacteria, including Prevotella,
Streptococcus, Neisseria, and Haemophilus. In contrast,
U204 and U205 showed high-level domination by
Streptococcus, and U207 was dominated by Rothia. Viral
sequences were rare in oral sample.
In nasopharyngeal samples (Fig. 4b), healthy subjects
were dominated by Moraxella, Staphylococcus, and Pro-
pionibacterium. Bradyrhizobium was detected in B207
and healthy subjects, but this is a soil bacteria and a
common contaminant, so we infer that detection of this
lineage is artifactual. SCID subjects contained normal
lineages to varying degrees, but also showed high-level
colonization by Streptococcus, Corynebacterium, and
others. In addition, nasopharyngeal samples from U203
were dominated by Bocavirus.
We compared the full microbial compositions of the
samples using Bray-Curtis dissimilarities and found that
sample types clustered by body site of origin (Fig. 5a,
PERMANOVA p value < 0.001), as expected from many
studies. Nasopharyngeal swabs also clustered near the
reagent controls, suggesting that low authentic microbial
biomass was present in these samples and that a signifi-
cant proportion of the reads were likely derived from en-
vironmental contamination. We also found that each
subject clustered with themselves throughout all time-
points, reflecting consistently higher inter-subject dif-
ferences than intra-subject differences (PERMANOVA
p value < 0.001). In several patients (U201, U205, and
U207), the gut microbial communities began resem-
bling healthy children more at late times after cell infu-
sion (Fig. 5b), potentially reflecting a combination of
improving immune function and reduction in usage of
antibiotics and other medications. U203 and F201,
whose microbial communities remained abnormal through-
out the sampling period, were on prolonged antibiotics for
treatment of disseminated Bacille Calmette-Guerin after
gene therapy, potentially contributing to dysbiosis.
Analysis of taxonomic richness provides insight into
microbial community health, since low richness is often
associated with abnormal outgrowth of pathogenic or-
ganisms. For stool, richness increased for 4/6 subjects
over time, potentially indicative of improving gut health
(Fig. 5c). However, of the four subjects for whom oral sam-
ples were available, all showed abnormally low richness at
every time point. This finding was associated with particu-
larly high Streptococcus colonization in multiple subjects.
Nasopharyngeal microbiota showed richness comparable
to healthy controls.
SCID patients were treated with a wide variety of anti-
biotics before and after therapy to mitigate opportunistic
infections. To assess whether this treatment was associ-
ated with an increase in antibiotic resistance gene repre-
sentation, we quantified antibiotic resistance genes in
the stool sequence samples using ShortBRED and the
CARD antibiotic resistant factor database (Fig. 5d). We
saw a greater quantity of antibiotic resistance genes in
SCID subjects than in healthy controls in stool (pooled
across timepoints, p = 0.048). Particularly high levels were
seen in U204, for whom gene therapy was unsuccessful.
Lesser frequencies of antibiotic resistance genes were evi-
dent in the oropharyngeal and nasopharyngeal samples.
For patient U201, who had a timepoint 24 months after
therapy, the level of antibiotic resistance genes decreased
substantially between the 5- and 24-month timepoint. At
this timepoint, the patient was no longer on any medica-
tions, which suggests that antibiotic resistance gene load
may have decreased after the selective antibiotic was with-
drawn. This suggests that the antibiotic administration,
and potentially hospitalization, increased antibiotic resist-
ance gene proportions.
Response of the virome
To enrich for virus detection beyond what was identified
in whole stool sequencing (as in Fig. 4), viral particles
were purified from stool, and DNA and RNA purified
from particles and sequenced. Only patients with suffi-
cient material were able to be virome-sequenced (patients
U207 and F201 were excluded). Reads were assigned using
Kraken, then extensive filtering was carried out to remove
contaminants and artifacts. Figure 6 shows the remaining
attributions. For RNA viruses, high-level colonization was
detected with Astrovirus (U204 and U205) and Sapovirus
(U203). For DNA viruses, numerous bacteriophage line-
ages were seen. Among DNA viruses infecting animal
cells, high viral loads were seen for Adenovirus in U201,
Bocavirus in U203, and Betatorquetenovirus (Anellovirus)
in U205. The Adenovirus and Bocavirus infections di-
minished over time after successful gene correction.
Betatorquetenovirus is a normal commensal in healthy
individuals and persisted.
Discussion
We present here an initial analysis of the co-development
of the microbiome and immune system in patients after
gene therapy for SCID. We used targeted sequencing of
vector integration sites to model the number of gene-cor-
rected progenitor cells and TCR sequencing to capture
the development of the T cell repertoire following therapy.
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The combination of these data allowed a lower-bound ap-
proximation of the number of cell divisions required to
progress from a lymphoid progenitor cell to a circulating
T cell, a measurement uniquely possible due to the com-
bined analysis. We used shotgun metagenomic sequencing
in longitudinal samples to track early-term changes in the
gut, oral, and nasopharyngeal microbiome accompanying
therapy. In a subset of these timepoints, we purified and
sequenced RNA and DNA viruses, revealing clearance of
several viruses associated with immune reconstitution.
The TCR-beta CDR3 analysis provided new evidence on
how SCID gene therapy patients progressed to healthier
phenotypes after successful therapy. After successful recon-
stitution, their T cell richness, as measured by TCR-beta
sequencing, consistently moved from the oligoclonal range
to a polyclonal range characteristic of healthy children.
Further, their V and J usage generally showed a pattern typ-
ical of a healthy and age-typical state. This is concordant
with the observed results of healthy immune function in
these patients and shows that sequencing metrics of the T
cell repertoire correlated with clinical outcomes here. A
number of patient repertoires had outgrowths of expanded
clones, possibly due to response to antigens. We found
lower T cell diversity in SCIDn1 patients than healthy con-
trols, which may indicate a slow but gradual loss of diver-
sity with time after therapy.
Comparison of the population sizes of progenitor cells,
marked by unique integration sites, and T cell clones,
marked by unique TCR-beta sequences, suggested that
intrathymic cell expansion from progenitors to T cells
involved at least nine cell divisions. In comparison with
our result, a related estimate was derived from a study
of a SCID-X1 patient with spontaneous reversion of a
IL2RG point mutation, in which descendants of a single
reverted progenitor cell repopulated the immunodefi-
cient subject [53]. In that case, it was estimated that at
least 10 cell divisions were required to expand the sin-
gle revertant T cell progenitor to yield the observed
1000 TCR-beta clonotypes. Though we note that both
methods have large and uncharacterized uncertainties,
the two yield notably similar results. In the case of
SCID-X1 gene therapy, if (very roughly) 1000 progenitor
(See figure on previous page.)
Fig. 5 Microbiome community analysis. a Sample clustering using Bray-Curtis dissimilarity. Different sample types are marked by the colors, healthy
versus SCID are shown by the shapes. b Comparison of stool samples for each patient queried to healthy controls. Samples were clustered using
Bray-Curtis dissimilarity. Each panel compares one SCID subject samples (indicated at the top) to healthy control samples (shown in gray). Elapsed time
is shown using the color code (bottom). c The longitudinal species richness of each patient’s oral, nasal, and stool samples is shown in separate panels.
The 95% CI of the healthy child richness for that sample type is shown in tan. d Representation of selected antibiotic resistance genes in the stool
samples studied. Each column indicates a metagenomic data set from the subject listed at the top. Each row summarizes the abundance of an
antibiotic resistance gene class. The tiles are colored by reads per kilobase of target per million sequence reads (RPKM); the color code is to
the right of the panel
A
B
Fig. 6 Virome analysis. a Heat map summarizing RNA viruses detected. Each column indicates a sample from the patient indicated at the top of
the heatmap, each row indicates a type of virus. The tiles are colored according to abundance. b Heat map summarizing DNA viruses detected.
Markings as in A
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cells supported long-term immune reconstitution, then
about 10 cell divisions (210 = 1024) would be required to
reach the same final population size of around 1 million
distinct T cell clones with unique TCR-beta sequences.
Each clone will then further expand in the periphery to
allow the production of the patient final T cell pool con-
taining around 109 T lymphocytes (about 10 additional di-
visions). In comparison, in the revertant subject, 20
additional divisions will be required to allow the produc-
tion of the final T cell pool in the periphery. That is, 10 di-
visions in gene therapy subjects and 20 in the revertant
would produce a similar final population size. Implicit in
these observations is the hypothesis that there exists a
feedback mechanism that determines the final size of the
T cell pool.
As with their TCR repertoires, the microbiota of
several successfully treated patients changed to more
resemble those of healthy children. We saw an increase
in diversity and richness of the microbes in the gut,
oro- and nasopharyngeal compartments, and an out-
growth of bacteria associated with healthy gut func-
tion. In some patients, we were also able to detect
bacteria that may be associated with negative outcomes
and antibiotic resistance, potentially as a result of ex-
tended exposure to antibiotics and hospitalization. In
one patient where longer term samples were available,
we documented a loss of antibiotic resistance genes at
the last time point, suggesting that maintenance of the
resistant population is largely reliant on the selective
pressure exerted by the drug. NK cell reconstitution in
SCID patients is variable, so our data emphasize the
importance of T cells in regulating the microbiota ver-
sus NK cells [19, 54].
An unexpected finding was the consistently low diver-
sity of SCID oral samples, and the high colonization with
Streptococcus. It will be of interest to assess whether this
is seen in other immunodeficient subjects, and target
investigations of possible pathology associated with
Streptococcus.
In some patients, we found viruses known to cause
enteropathic conditions in humans, including Astro-
virus, Bocavirus, and Adenovirus. In the case of patient
U207, the adenovirus detection was corroborated with a
clinical assay, and for U203, Bocavirus was detected clin-
ically, supporting the reliability of the metagenomic de-
tections. In each, the relative abundance of viral reads
was diminished at later timepoints, likely as a result at
least in part of engagement of the newly functioning im-
mune system.
This study has several limitations. Most significantly,
our sample size was quite small. In addition, clinical con-
siderations often led to inconsistent sampling based on
patient and clinician availability. These considerations
limit our ability to draw broad conclusions.
Opportunities to study similar systems of immune sys-
tem/microbiome dynamics are present in SCID patients
who undergo hematopoietic stem cell transplantation
(HSCT). A pilot study investigated microbiome develop-
ment in SCID patients after HSCT [55], though with
16S gene tag sequencing rather than shotgun sequen-
cing, no healthy controls, a shorter sampling period, and
no concurrent TCR sequencing. They found inconsistent
results in microbiome diversity after transplantation,
possibly due to the limited temporal range of the study,
but did note that there were clear differences in the
microbiota before and after transplantation in the four
subjects studied.
Conclusions
This study illustrates some of the uses of multi-omic
data in assessing outcome in human gene therapy, in-
cluding specifying aspects of T cell development and
normalization of the microbiota with restoration of T
cell function. As more of these studies are carried out, it
will be possible to assess more fully the utility of such
data. Of particular interest will be any signatures that
help forecast outcome and provide new opportunities
for initiating therapeutic interventions.
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